277 results on '"Baum, R."'
Search Results
2. Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors
3. PSMA radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry
4. Long-Term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients with Refractory Meningioma
5. SSTR-Antagonist [68Ga]Ga-DATA5m-LM4 zu Bildgebung von gut differenzierten neuroendokrinen Tumoren: von der Produktion zu ersten klinischen Ergebnissen
6. Von der vollautomatischen Synthese von [68Ga]Ga-DATA5m.SA.FAPi zu ersten klinischen Untersuchungen
7. Radiolabeling of 3BP-3940 with 68Ga, 90Y, 177Lu and 225Ac for imaging and Peptide Targeted Radiotherapy (PTRT)
8. Long-Term Tolerability, Efficacy and Survival of Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors of Unknown Primary (CUP-NETs)
9. FAP-Peptidvermittelte Radiorezeptortherapie (PTRT) bei soliden Tumoren: erste klinische Erfahrungen mit dem 177Lu-, 225Ac- oder 90Y-markierten Peptid 3BP-3940
10. First-in-human Study of an Optimized, Kit-type, SSTR Antagonist 68Ga-DATA5m-LM4 in Patients with Metastatic Neuroendocrine Tumors
11. Fibroblast Activating Protein (FAP)-Targeted Radiopeptide Therapy using 177Lu-, 225Ac- and 90Y-labeled 3BP-3940 in Diverse Advanced Solid Tumors: First-in-Humans Results
12. Einfluss der PSMA-Radioligandentherapie (PRLT) auf die Immunogenität einer Impfung gegen SARS-CoV-2 - eine retrospektive einarmige Kohortenstudie bei Patienten mit metastasierten Prostatakarzinomen
13. HTA163 Development of SF-6Dv2 Health Utility Weights in the United States
14. Simulated effect of topography and soil properties on hydrologic response and landslide potential under variable rainfall conditions in the Oregon Coast Range, USA
15. POSC381 Derivation of Interpretation Thresholds for the SF-36V2® Health Survey (SF-36V2) in Rheumatoid Arthritis
16. POSA378 Derivation of Interpretation Thresholds for the Rheumatoid Arthritis Symptoms and Impact Questionnaire (RASIQ) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FATIGUE) Scale
17. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival
18. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry
19. Klinische Indikationen
20. Capturing landslide dynamics and hydrologic triggers using near-real-time monitoring
21. Receptor PET/CT Imaging of Neuroendocrine Tumors
22. G128(P) ‘Assessment to treat rather than admission to assess’: establishing a permanent paediatric assessment unit at a district general hospital
23. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
24. Modeling time-dependent areal slope stability
25. Landslide susceptibility from topography in Guatemala
26. Die Wertigkeit der PET in der Nachsorge des kolorektalen Karzinoms
27. 18-FDG-PET in Diagnosestellung und Verlauf bei Patienten mit Dermatomyositis
28. Ergebnisse in den Neurologischen Kliniken
29. Clinical Indications
30. Positronenemissionstomographie des Herzens
31. Ganzkörper Fluor-18-Fluordeoxyglukose (FDG)-PET zum Nachweis okkulter metastasierter Schilddrüsenkarzinome
32. Biodistribution and Biokinetics of the Tc-99m-Labeled Murine Monoclonal Anti-EGF Receptor Antibody Mab 425 in Nude Mice
33. Intraoperative Rezidivlokalisation von medullären Schilddrüsenkarzinomen mittels einer Gammasonde: erste klinische Ergebnisse
34. Wertigkeit der Immunszintigraphie in der Diagnostik von HNO-Karzinomen
35. PSY3 PSYCHOMETRIC VALIDATION OF FACIT-FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS
36. CL3 UNDERSTANDING THE PATIENT VOICE IN COMPARATIVE EFFECTIVENESS STUDIES: THE ROLE OF BENCHMARK COMPARISONS
37. Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)
38. Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a Phase 3, randomised, controlled trial (EXPAND)
39. Möglichkeiten und Grenzen der Immunszintigraphie in der Diagnostik des Ovarialkarzinoms
40. Onkologie I: Klinik
41. S68 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis homozygous for F508del-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial (EVOLVE)
42. S67 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a phase 3 randomized, controlled trial (EXPAND)
43. Klinische, sonographische und immunologische Spätergebnisse 5–10 Jahre nach Autotransplantation der Milz
44. Novel Monoclonal Antibody 138H11 Against Human γ-Glutamyl-Transferase: Classification, Histogenesis and Immunoscintigraphy of Renal Tumors
45. Chemoembolization of Hepatic Tumors with Degradable Starch Microspheres
46. Six Years of Experience with Local Chemotherapy of the Liver
47. PRM197 - RESPONDER DEFINITION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS)-29 V2 AMONG PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
48. PMU87 - HEALTH STATE UTILITY FOR COMORBID CONDITIONS: EVALUATING THE IMPACT OF DIFFERENT ESTIMATION METHODS
49. P3497Carcinoid heart disease in patients with neuroendocrine tumours: prevalence and predisposing factors
50. Somatostatinrezeptor-PET/CT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.